BioXcel Therapeutics Inc
$ 1.61
-2.42%
05 Mar - close price
- Market Cap 35,209,900 USD
- Current Price $ 1.61
- High / Low $ 1.83 / 1.58
- Stock P/E N/A
- Book Value -4.45
- EPS -9.29
- Next Earning Report 2026-03-26
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.67 %
- ROE -17.67 %
- 52 Week High 8.08
- 52 Week Low 1.17
About
BioXcel Therapeutics, Inc., a clinical-phase biopharmaceutical company, focuses on the development of artificial intelligence-based drugs in the fields of neuroscience and immuno-oncology in the United States. The company is headquartered in New Haven, Connecticut.
Analyst Target Price
$14.25
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-12 | 2025-08-12 | 2025-05-07 | 2025-03-10 | 2024-11-12 | 2024-08-06 | 2024-05-09 | 2024-03-12 | 2023-11-14 | 2023-08-14 | 2023-05-08 | 2023-03-09 |
| Reported EPS | -2.18 | -2.45 | -1.5 | -3.5627 | -0.32 | -0.21 | -0.87 | -0.76 | -1.72 | -1.83 | -1.84 | -1.95 |
| Estimated EPS | -0.09 | -0.13 | -3.04 | -5.1433 | -0.54 | -0.71 | -0.7 | -0.91 | -1.3 | -1.75 | -1.62 | -1.45 |
| Surprise | -2.09 | -2.32 | 1.54 | 1.5806 | 0.22 | 0.5 | -0.17 | 0.15 | -0.42 | -0.08 | -0.22 | -0.5 |
| Surprise Percentage | -2322.2222% | -1784.6154% | 50.6579% | 30.7312% | 40.7407% | 70.4225% | -24.2857% | 16.4835% | -32.3077% | -4.5714% | -13.5802% | -34.4828% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-26 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.34 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BTAI
2026-03-05 13:52:27
BioXcel Therapeutics Inc. (NASDAQ: BTAI) stock surged over 15% due to investor optimism following a positive market opportunity assessment for its treatment, Igalmi, for acute agitation associated with bipolar disorders and schizophrenia, especially for at-home use. The company is also advancing BXCL501 for Alzheimer’s dementia and is positioned for future growth despite current financial challenges. While the strategic moves signal a brighter future, smart cash flow management and cautious investing are advised.
2026-03-05 11:52:27
BioXcel Therapeutics has announced positive topline results from a Columbia University-led Phase 2 study of BXCL501, their drug candidate for treating opioid withdrawal. The news led to a significant premarket rise in the company's shares. This development positions BXCL501 as a potential treatment for agitation associated with opioid withdrawal in both inpatient and outpatient settings.
2026-03-05 11:52:27
BioXcel Therapeutics (BTAI) saw a significant 16.36% price increase in pre-market trading, defying a general market decline, due to sector rotation towards biotech stocks. Analysts from Mizuho and H.C. Wainwright have raised their price targets for BTAI, citing positive Phase 3 study data for BXCL501 and "heightened enthusiasm" for its prospects. The company is actively developing BXCL501 for psychiatric and neurological disorders, including potential at-home use, and recently reported positive Phase 2 results for opioid withdrawal treatment, suggesting significant market potential.
2026-03-05 11:52:27
BioXcel Therapeutics (BTAI) announced positive Phase 2 topline results for its drug BXCL501 in treating opioid withdrawal symptoms. The Columbia University-led study showed that BXCL501 significantly reduced withdrawal symptoms and had a more favorable tolerability profile, including lower rates of orthostatic hypotension and no sedation, compared to lofexidine. These findings suggest BXCL501 could be a promising non-opioid, orally dissolving thin-film alternative for managing opioid withdrawal, particularly from fentanyl/xylazine exposure.
2026-03-04 04:51:44
BioXcel Therapeutics Inc (BTAI) is currently in the "Fair zone" according to its valuation, with a forward PS ratio of 27.88 compared to a five-year average of -2.42. The fair price for BTAI is estimated between $0.15 to $2.24 using a relative valuation method. Despite a high P/S ratio compared to competitors, the article suggests this premium might be unsustainable given the company's revenue growth.
2026-02-27 13:52:16
This article provides a detailed financial overview of Bioxcel Therapeutics Inc (BTAI), including its income statement, balance sheet, and cash flow statement. It highlights key financial metrics for fiscal year 2024, such as revenue of $2.3M, net income of -$59.6M, and diluted EPS of -$23.51. The analysis also covers financial health signals like a weak Piotroski F-Score of 2/9, low earnings quality, and at-risk interest coverage, indicating significant financial challenges for the company.
